Recombinant Dog Vesicular integral-membrane protein VIP36 (LMAN2)

What is Vesicular Integral-Membrane Protein VIP36 (LMAN2) and what is its biological significance?

Vesicular integral-membrane protein VIP36, also known as Lectin mannose-binding 2 (LMAN2), is a type I membrane protein that functions as a mannose-specific lectin in the early secretory pathway. It plays a critical role in protein trafficking and quality control within the cell. The protein is primarily localized in the Golgi apparatus and cycles between the Golgi and endoplasmic reticulum (ER).

In canine species (Canis familiaris), LMAN2 functions as a cargo receptor that recognizes high-mannose type glycans on glycoproteins, facilitating their transport through the secretory pathway. The biological significance of LMAN2 lies in its contribution to protein folding quality control and the transport of specific glycoproteins between cellular compartments .

The canine LMAN2 protein shares significant homology with human and mouse orthologs, making it valuable for comparative studies across species. Research on dog LMAN2 can provide insights into conserved functions of this protein family across mammals.

What expression systems are most effective for producing Recombinant Dog LMAN2?

Multiple expression systems have been successfully employed for producing Recombinant Dog LMAN2, each with specific advantages based on research requirements. The following table summarizes these systems and their characteristics:

How can researchers verify the identity and integrity of purified Recombinant Dog LMAN2?

Verification of recombinant LMAN2 identity and integrity requires a multi-pronged analytical approach. The following methodologies are recommended:

• SDS-PAGE analysis: To assess purity and apparent molecular weight. Properly expressed and purified Dog LMAN2 should demonstrate a purity of greater than or equal to 85% as determined by SDS-PAGE .

• Western blot verification: Using specific antibodies against LMAN2 or tags (such as His-tag if incorporated). Cross-reactivity with antibodies developed against other species' LMAN2 may be possible due to sequence conservation.

• Mass spectrometry analysis: For precise molecular weight determination and peptide mapping. This approach can confirm the sequence identity and detect any post-translational modifications or proteolytic processing.

• Lectin binding assays: Since LMAN2 is a mannose-binding lectin, functional validation through carbohydrate binding assays provides evidence of proper folding and activity.

• Circular dichroism (CD) spectroscopy: To analyze secondary structure elements, confirming proper protein folding.

The validation approach should be tailored to the intended application, with more stringent verification required for structural studies compared to preliminary screening experiments.

What are the critical factors affecting the functional activity of Recombinant Dog LMAN2 in experimental settings?

The functional activity of Recombinant Dog LMAN2 is influenced by several critical factors that researchers must carefully control in experimental settings:

• Calcium dependency: LMAN2's carbohydrate-binding activity is calcium-dependent. Experiments should maintain physiological calcium concentrations (approximately 1-2 mM Ca²⁺) in buffers to preserve lectin functionality.

• pH sensitivity: LMAN2 exhibits optimal binding activity in slightly acidic to neutral pH (6.5-7.5), reflecting its native environment in the early secretory pathway. Experimental buffers should be maintained within this range for functional studies.

• Glycosylation status: As LMAN2 itself is glycosylated, the expression system employed affects its own glycosylation pattern, potentially impacting folding and function. Mammalian expression systems provide the most native-like glycosylation.

• Membrane association: Full-length LMAN2 is a membrane protein with a transmembrane domain. Studies requiring membrane-associated LMAN2 should consider using detergent-solubilized preparations or reconstitution into liposomes or nanodiscs to maintain a lipid environment.

• Oligomerization state: LMAN2 can form oligomers that may affect its binding properties. Size-exclusion chromatography can help verify the oligomeric state of the recombinant protein.

When designing functional assays for LMAN2, these factors should be systematically controlled and reported. Researchers should validate activity through carbohydrate binding assays using glycoprotein substrates or synthetic glycans with high-mannose structures.

How can researchers optimize purification protocols for Recombinant Dog LMAN2 to maximize yield while maintaining functionality?

Optimizing purification protocols for Recombinant Dog LMAN2 requires balancing yield with functional integrity. The following methodological approach addresses common challenges:

• Lysis buffer optimization:

  • For bacterial expression: Use mild detergents (0.5-1% Triton X-100 or NP-40) with protease inhibitors

  • For mammalian expression: Consider membrane fractionation before solubilization with detergents like DDM (n-Dodecyl β-D-maltoside) at 1%

  • Maintain pH 7.0-7.5 and include 1-2 mM CaCl₂ to preserve lectin domain structure

• Affinity purification strategies:

  • His-tagged proteins: Use Ni-NTA or TALON resin with imidazole gradients (20-250 mM)

  • Include detergent at concentrations above critical micelle concentration (CMC) if purifying full-length membrane-associated protein

  • Consider mannose-agarose affinity chromatography for functional enrichment

• Polishing steps:

  • Size exclusion chromatography separates monomeric from oligomeric forms and removes aggregates

  • Ion exchange chromatography provides additional purity, particularly for E. coli-expressed proteins

• Stability considerations:

  • Add glycerol (10-15%) to storage buffers to prevent freeze-thaw damage

  • Maintain calcium (1 mM CaCl₂) in all buffers

  • Consider flash-freezing in small aliquots to avoid repeated freeze-thaw cycles

Following this approach, researchers can achieve greater than 95% purity while maintaining functional integrity, as assessed by mannose-binding activity assays and structural analyses .

What experimental approaches are most effective for studying LMAN2 interactions with cargo glycoproteins?

Investigating LMAN2 interactions with cargo glycoproteins requires specialized methodologies that preserve the native binding characteristics. Several complementary approaches are recommended:

• Surface Plasmon Resonance (SPR):

  • Immobilize purified LMAN2 on sensor chips via amine coupling or capture approaches

  • Flow potential cargo glycoproteins at various concentrations

  • Determine association and dissociation kinetics (kon and koff)

  • Include calcium controls (EGTA negative control) to confirm specificity

• Pull-down and co-immunoprecipitation assays:

  • Use purified LMAN2 with His-tag or other affinity tags

  • Incubate with cellular lysates or purified candidate cargo proteins

  • Analyze bound proteins by Western blot or mass spectrometry

  • Compare binding in calcium-containing versus calcium-depleted conditions

• Glycan array screening:

  • Test LMAN2 binding to panels of immobilized glycan structures

  • Identify specific glycan motifs recognized by dog LMAN2

  • Compare with human and mouse orthologs to identify species-specific preferences

• Proximity labeling approaches:

  • Create LMAN2 fusions with promiscuous biotin ligases (BioID) or peroxidases (APEX)

  • Express in cell culture systems to identify proximal interacting proteins

  • Analyze biotinylated proteins by mass spectrometry

• Fluorescence-based approaches:

  • Fluorescence Resonance Energy Transfer (FRET) between labeled LMAN2 and cargo

  • Microscale Thermophoresis (MST) for quantitative binding measurements

  • Fluorescence Recovery After Photobleaching (FRAP) for membrane dynamics studies

These methodologies should be employed with appropriate controls, including calcium dependency validation and comparison with LMAN2 mutants defective in glycan binding.

What are common pitfalls when working with Recombinant Dog LMAN2 and how can they be addressed?

Researchers working with Recombinant Dog LMAN2 frequently encounter several challenges that can impact experimental outcomes. This table outlines common pitfalls and their solutions:

When troubleshooting experimental issues with LMAN2, researchers should systematically evaluate each of these potential causes, beginning with protein quality control assessments using SDS-PAGE, Western blotting, and activity assays before proceeding to more complex experimental setups.

How should researchers design comparative studies between canine LMAN2 and its homologs in other species?

Designing rigorous comparative studies between canine LMAN2 and its homologs requires careful experimental planning to isolate species-specific differences from methodological variations. The following framework provides methodological guidance:

• Sequence and structural analysis:

  • Perform comprehensive sequence alignments of LMAN2 across target species

  • Identify conserved domains versus variable regions

  • Model structures using available crystal structures as templates

  • Generate hypotheses about functional differences based on sequence/structural variations

• Standardized expression and purification:

  • Express all species variants in the same expression system

  • Utilize identical purification protocols and buffer conditions

  • Verify comparable purity (>95% by SDS-PAGE) and integrity for all proteins

  • Document yields and behavior during purification as potential species differences

• Biochemical characterization:

  • Determine oligomerization states through size exclusion chromatography

  • Measure thermal stability using differential scanning fluorimetry

  • Analyze secondary structure content through circular dichroism

  • Quantify calcium binding affinities through isothermal titration calorimetry

• Glycan binding profiling:

  • Employ glycan arrays with identical conditions for all species variants

  • Determine binding specificities and affinities through surface plasmon resonance

  • Validate key interactions with isothermal titration calorimetry

  • Compare pH and calcium dependency of binding interactions

• Cellular localization and trafficking:

  • Express fluorescently-tagged variants in the same cell line

  • Track localization and trafficking using live cell imaging

  • Quantify retention in cellular compartments through fractionation studies

  • Measure protein half-life and degradation pathways

By implementing this systematic approach, researchers can distinguish genuine species-specific differences from methodological artifacts, providing insights into the evolutionary conservation and specialization of LMAN2 function across species.

What methodologies are recommended for analyzing the role of LMAN2 in glycoprotein quality control pathways?

Investigating LMAN2's role in glycoprotein quality control requires integrating multiple methodological approaches to elucidate its function in cellular contexts:

• CRISPR/Cas9-mediated knockout or knockdown studies:

  • Generate LMAN2-deficient cell lines through CRISPR/Cas9 genome editing

  • Establish conditional knockdown systems using shRNA or siRNA approaches

  • Analyze secretion efficiency of known cargo glycoproteins

  • Perform rescue experiments with wild-type and mutant LMAN2 variants

• Pulse-chase analysis of glycoprotein trafficking:

  • Metabolically label cells with radioactive amino acids or clickable analogs

  • Chase for varied time periods to track glycoprotein maturation

  • Immunoprecipitate specific cargo proteins from cellular fractions

  • Compare trafficking kinetics between wild-type and LMAN2-deficient cells

• Glycan profiling of secreted proteins:

  • Analyze N-glycan structures using mass spectrometry

  • Compare glycan profiles between control and LMAN2-deficient cells

  • Look for accumulation of immature glycoforms in LMAN2-deficient conditions

  • Correlate glycan structures with LMAN2 binding preferences

• Proximity labeling approaches:

  • Generate LMAN2 fusions with BioID or APEX2

  • Identify proteins in proximity to LMAN2 in different cellular compartments

  • Compare interactomes under normal versus stress conditions

  • Validate key interactions through co-immunoprecipitation

• Super-resolution microscopy:

  • Perform multi-color imaging of LMAN2 with ER, ERGIC, and Golgi markers

  • Track dynamic movements using live-cell imaging approaches

  • Quantify co-localization with candidate cargo proteins

  • Analyze changes in localization under different cellular conditions

These complementary approaches provide a comprehensive analysis of LMAN2's functional role in quality control and trafficking of glycoproteins, revealing both mechanistic insights and physiological significance.

How can structural studies of Recombinant Dog LMAN2 inform drug discovery targeting the lectin-glycoprotein interaction network?

Structural studies of Recombinant Dog LMAN2 can provide crucial insights for drug discovery efforts targeting lectin-glycoprotein interactions. This methodological approach integrates multiple techniques to facilitate structure-based drug design:

• High-resolution structure determination:

  • X-ray crystallography of the carbohydrate recognition domain (CRD)

  • Use of synthetic glycan ligands to co-crystallize protein-carbohydrate complexes

  • Cryo-electron microscopy for full-length protein in membrane environments

  • NMR studies focusing on ligand binding dynamics

• Binding site characterization:

  • Identification of key residues involved in mannose recognition

  • Mapping the calcium coordination sites critical for function

  • Characterization of binding site plasticity through molecular dynamics simulations

  • Comparison with human LMAN2 to identify species-specific binding features

• Fragment-based screening approaches:

  • Development of assays to detect binding of small molecule fragments

  • Thermal shift assays to identify stabilizing compounds

  • NMR-based screening for binding site identification

  • Crystallographic fragment screening for structural validation

• In silico drug discovery methods:

  • Virtual screening against the characterized binding pockets

  • Molecular docking of glycomimetic compounds

  • Molecular dynamics simulations to predict binding energetics

  • Development of pharmacophore models based on natural ligands

• Rational design of modulators:

  • Design of glycomimetics that selectively target the CRD

  • Development of allosteric modulators affecting oligomerization

  • Creation of stabilized peptides mimicking cargo protein binding motifs

  • Design of bifunctional molecules for targeted protein degradation approaches

These structural studies can ultimately guide the development of compounds that modulate LMAN2-dependent trafficking, potentially addressing disorders associated with protein misfolding and trafficking defects.

What are the considerations for developing and validating LMAN2 knockout models for studying protein trafficking defects?

Developing and validating LMAN2 knockout models requires careful consideration of multiple factors to ensure physiological relevance and interpretable results. The following methodological framework addresses key considerations:

• Model system selection:

  • Cell line models: Choose relevant cell types expressing LMAN2-dependent cargo proteins

  • Organismal models: Consider viability, compensatory mechanisms, and available genetic tools

  • Species selection: Evaluate conservation of LMAN2 function across species

  • Conditional versus constitutive approaches: Balance developmental effects versus acute responses

• Knockout strategy design:

  • CRISPR/Cas9 targeting: Design guides targeting early exons to ensure complete loss of function

  • Verification strategies: Implement multiple methods to confirm knockout at DNA, RNA, and protein levels

  • Control for off-target effects: Use multiple guide RNAs and rescue experiments

  • Consider tissue-specific or inducible knockout systems to bypass developmental requirements

• Validation requirements:

  • Genomic validation: Sequence target loci to confirm editing events

  • Transcript analysis: Verify absence of LMAN2 mRNA and check for cryptic splicing

  • Protein verification: Confirm complete absence of protein using validated antibodies

  • Functional validation: Demonstrate altered trafficking of known LMAN2 cargo proteins

• Phenotypic characterization:

  • Proteomics: Quantitative analysis of secreted proteins and cellular glycoproteins

  • Glycomics: Analysis of glycan structures on secreted and membrane proteins

  • Cell biology: Evaluate ER stress markers, UPR activation, and secretory pathway morphology

  • Physiological assessment: Analyze tissue-specific effects related to secretory pathway function

• Controls and rescue experiments:

  • Include wild-type controls with identical genetic background

  • Develop rescue lines expressing wild-type LMAN2 to confirm specificity

  • Create rescue lines with mutant LMAN2 variants to dissect functional domains

  • Consider compensation by related proteins (e.g., LMAN2L/VIP36L) through parallel knockouts

This comprehensive approach ensures that findings from LMAN2 knockout models are specifically attributable to LMAN2 deficiency rather than technical artifacts or compensatory mechanisms.

How can researchers leverage comparative studies between LMAN2 and LMAN2L to understand their distinct and overlapping functions?

LMAN2 and LMAN2L (VIP36 and VIP36-like protein) share structural similarities yet display distinct cellular functions. A methodological framework for comparative studies includes:

• Biochemical comparison approach:

  • Express and purify both proteins using identical systems

  • Compare glycan binding specificities using glycan arrays

  • Determine binding affinities for shared and distinct ligands

  • Analyze pH and calcium dependency differences

  • Characterize oligomerization properties and membrane association

• Structural comparative analysis:

  • Obtain high-resolution structures of both proteins

  • Perform detailed binding site comparisons

  • Identify structural determinants of binding specificity differences

  • Create chimeric proteins swapping domains between LMAN2 and LMAN2L

  • Test chimeras for altered localization and cargo recognition

• Cellular localization and dynamics:

  • Generate fluorescently tagged versions of both proteins

  • Track intracellular localization in live cells

  • Measure trafficking rates between compartments

  • Identify sorting signals directing differential localization

  • Analyze responses to secretory pathway stressors

• Cargo identification strategy:

  • Perform proximity labeling (BioID/APEX) with both proteins

  • Compare interactomes to identify unique and shared partners

  • Validate key interactions through co-immunoprecipitation

  • Assess competition between LMAN2 and LMAN2L for shared cargo

  • Map binding determinants on cargo proteins

• Functional redundancy assessment:

  • Generate single and double knockout cell lines

  • Perform rescue experiments with each protein

  • Analyze synthetic phenotypes in double knockout models

  • Test cross-complementation with mutant variants

  • Evaluate evolutionary conservation of separate functions

This systematic comparative approach will reveal how these related proteins have evolved distinct but complementary roles in glycoprotein quality control and trafficking, providing insights into the complexity of the early secretory pathway.

What are the key knowledge gaps in LMAN2 research that require further investigation?

Despite significant advances in understanding LMAN2 function, several critical knowledge gaps remain that limit our comprehensive understanding of this protein's role in cellular physiology:

• Species-specific functional differences remain poorly characterized, particularly between canine LMAN2 and its homologs in other mammals. The detailed binding preferences, trafficking patterns, and cargo selectivity across species require systematic comparative analysis.

• The complete repertoire of physiological cargo proteins recognized by LMAN2 remains undefined. While some cargo proteins have been identified, a comprehensive cargo landscape would provide insights into the biological significance of LMAN2-mediated trafficking.

• The regulatory mechanisms controlling LMAN2 expression, localization, and activity under different cellular conditions (stress, differentiation, disease states) remain largely unexplored. Understanding these regulatory circuits would reveal how LMAN2 function is integrated with broader cellular processes.

• The structural basis for cargo recognition selectivity is incompletely understood. While LMAN2 binds high-mannose glycans, the structural features that determine which glycoproteins are selected as cargo versus those that are not require elucidation.

• The potential roles of LMAN2 in pathological conditions, including protein misfolding diseases, lysosomal storage disorders, and cancer, represent an important frontier for translational research.

Addressing these knowledge gaps will require integration of structural biology, glycobiology, cell biology, and systems biology approaches, potentially revealing new therapeutic targets within the secretory pathway.

What methodological advances would facilitate more comprehensive studies of LMAN2 function?

Advancing our understanding of LMAN2 function requires innovative methodological approaches that address current technical limitations. The following emerging technologies and methodological developments would significantly enhance LMAN2 research:

• Advanced imaging approaches:

  • Super-resolution microscopy techniques (STORM, PALM, STED) to visualize LMAN2 trafficking with nanometer precision

  • Correlative light and electron microscopy (CLEM) to relate LMAN2 localization to ultrastructural features

  • Lattice light sheet microscopy for extended live-cell imaging with reduced phototoxicity

  • Phase separation detection methods to identify potential roles in membraneless organelles

• Glycobiology tools:

  • Chemoenzymatic labeling of specific glycan structures for tracking in living cells

  • Glycan editing technologies using CRISPR-based glycosyltransferase manipulation

  • Development of synthetic glycans with photoactivatable crosslinking capabilities

  • Single-molecule glycan analysis technologies for heterogeneity assessment

• Proteomics advances:

  • Quantitative glycoproteomics for comprehensive cargo identification

  • Proximity-dependent labeling with enhanced spatial and temporal resolution

  • Thermal proximity coaggregation for detecting weak or transient interactions

  • Organelle-specific proteomics to track cargo through the secretory pathway

• Structural biology innovations:

  • Time-resolved cryo-EM to capture conformational changes during binding events

  • Integrative structural biology approaches combining multiple data types

  • In-cell structural determination methods (e.g., FRET-based sensors, in-cell NMR)

  • Computational approaches for modeling glycosylated proteins in membrane environments

• Functional genomics tools:

  • Base editing and prime editing for precise genetic manipulation

  • CRISPRi/CRISPRa for reversible expression modulation

  • Single-cell transcriptomics combined with spatial information

  • Genetic interaction mapping using CRISPR screens